Human lives
drive our discovery
of microbiome therapeutics
Recurrent C. diff study
now enrolling
Learn more

Finch is a clinical-stage microbiome therapeutics company

leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs.

Human-First Discovery platform

With our platform we aim to rapidly translate insights mined from compelling human data into the development of novel microbiome therapeutics.

Learn more

Lead program

Our lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection, a debilitating and sometimes life-threatening disease.

Learn more

Recent news

Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results

November 10, 2022

Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference

November 09, 2022

Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection

October 24, 2022

Join us

Join us in our mission to transform the lives of patients and families fighting serious medical conditions.

Learn more